Paraptosis cell death induction by the thiamine analog benfotiamine in leukemia cells

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Sugimori, Naomi ^a   Espinoza, J Luis ^a   Trung, Ly Quoc ^a   Takami, Akiyoshi ^a,b   Kondo, Yukio ^a   An, Dao Thi ^a   Sasaki, Motoko ^c   Wakayama, Tomohiko ^c   Nakao, Shinji ^a  

^a KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^b AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BENFOTIAMINE; CYCLIN DEPENDENT KINASE 3; CYTARABINE; MITOGEN ACTIVATED PROTEIN KINASE 3; BENPHOTHIAMINE; CHELATING AGENT; THIAMINE; TUMOR MARKER;

ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL GROWTH; CELL VACUOLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; G1 PHASE CELL CYCLE CHECKPOINT; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PROTEIN PHOSPHORYLATION; ANALOGS AND DERIVATIVES; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECTS; LEUKEMIA, MYELOID, ACUTE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL CULTURE; WESTERN BLOTTING;

APOPTOSIS; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; CHELATING AGENTS; HUMANS; LEUKEMIA, MYELOID, ACUTE; PHOSPHORYLATION; THIAMINE; TUMOR CELLS, CULTURED;

EID: 84929485455     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0120709     Document Type: Article

References (34)

1. Doepfner KT, Boller D, Arcaro A (2007) Targeting receptor tyrosine kinase signaling in acute myeloid leukemia. Crit Rev Oncol Hematol 63: 215-230. PMID: 17658267
2. Yanada M, Naoe T (2012) Acute myeloid leukemia in older adults. Int J Hematol 96: 186-193. doi: 10. 1007/s12185-012-1137-3 PMID: 22791510
3. Eleni LD, Nicholas ZC, Alexandros S (2010) Challenges in treating older patients with acute myeloid leukemia. J Oncol 2010: 943823. doi: 10.1155/2010/943823 PMID: 20628485
4. Fey MF, Dreyling M, Group EGW (2010) Acute myeloblastic leukaemias and myelodysplastic syndromes in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21 Suppl 5: v158-161. doi: 10.1093/annonc/mdq179 PMID: 20555069
5. Motyckova G, Stone RM (2011) Treatment of elderly acute myeloid leukemia patients. Curr Treat Options Oncol 12: 341-353. doi: 10.1007/s11864-011-0162-4 PMID: 21901552
6. Balakumar P, Rohilla A, Krishan P, Solairaj P, Thangathirupathi A (2010) The multifaceted therapeutic potential of benfotiamine. Pharmacol Res 61: 482-488. doi: 10.1016/j.phrs.2010.02.008 PMID: 20188835
7. Fraser DA, Diep LM, Hovden IA, Nilsen KB, Sveen KA, et al. (2012) The Effects of Long-Term Oral Benfotiamine Supplementation on Peripheral Nerve Function and Inflammatory Markers in Patients With Type 1 Diabetes: A 24-month, double-blind, randomized, placebo-controlled trial. Diabetes Care 35: 1095-1097. doi: 10.2337/dc11-1895 PMID: 22446172
8. Shoeb M, Ramana KV (2012) Anti-inflammatory effects of benfotiamine are mediated through the regulation of the arachidonic acid pathway in macrophages. Free Radic Biol Med 52: 182-190. doi: 10. 1016/j.freeradbiomed.2011.10.444 PMID: 22067901
9. Schmid U, Stopper H, Heidland A, Schupp N (2008) Benfotiamine exhibits direct antioxidative capacity and prevents induction of DNA damage in vitro. Diabetes Metab Res Rev 24: 371-377. doi: 10.1002/ dmrr.860 PMID: 18384109
10. Schupp N, Dette EM, Schmid U, Bahner U, Winkler M, et al. (2008) Benfotiamine reduces genomic damage in peripheral lymphocytes of hemodialysis patients. Naunyn Schmiedebergs Arch Pharmacol 378: 283-291. doi: 10.1007/s00210-008-0310-y PMID: 18509620
11. Sakai I, Takeuchi K, Yamauchi H, Narumi H, Fujita S (2002) Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells. Blood 100: 2926-2931. PMID: 12351404
12. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, et al. (1991) NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 77: 1080-1086. PMID: 1995093
13. Furukawa T, Koike T, Ying W, Kishi K, Aoki S, et al. (1994) Establishment of a new cell line with the characteristics of a multipotential progenitor from a patient with chronic myelogenous leukemia in early erythroblastic crisis. Leukemia 8: 171-180. PMID: 8289484
14. Kitamura T, Takaku F, Miyajima A (1991) IL-1 up-regulates the expression of cytokine receptors on a factor-dependent human hemopoietic cell line, TF-1. Int Immunol 3: 571-577. PMID: 1832294
15. Espinoza JL, Takami A, Trung LQ, Kato S, Nakao S (2012) Resveratrol Prevents EBV Transformation and Inhibits the Outgrowth of EBV-Immortalized Human B Cells. PLoS One 7: e51306. doi: 10.1371/ journal.pone.0051306 PMID: 23251493
16. Sánchez-Ramírez GM, Caram-Salas NL, Rocha-González HI, Vidal-Cantú GC, Medina-Santillán R, et al. (2006) Benfotiamine relieves inflammatory and neuropathic pain in rats. Eur J Pharmacol 530: 48-53. PMID: 16359659
17. Quoc Trung L, Espinoza JL, Takami A, Nakao S (2013) Resveratrol Induces Cell Cycle Arrest and Apoptosis in Malignant NK Cells via JAK2/STAT3 Pathway Inhibition. PLoS One 8: e55183. doi: 10.1371/ journal.pone.0055183 PMID: 23372833
18. Luis Espinoza J, Takami A, Trung LQ, Nakao S (2013) Ataxia-telangiectasia mutated kinase-mediated upregulation of NKG2D ligands on leukemia cells by resveratrol results in enhanced natural killer cell susceptibility. Cancer Sci 104: 657-662. doi: 10.1111/cas.12141 PMID: 23445485
19. Kundu M, Thompson CB (2008) Autophagy: basic principles and relevance to disease. Annu Rev Pathol 3: 427-455. PMID: 18039129
20. Castro-Obregón S, Del Rio G, Chen SF, Swanson RA, Frankowski H, et al. (2002) A ligand-receptor pair that triggers a non-apoptotic form of programmed cell death. Cell Death Differ 9: 807-817. PMID: 12107824
21. Alkhalaf A, Klooster A, van Oeveren W, Achenbach U, Kleefstra N, et al. (2010) A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care 33: 1598-1601. doi: 10.2337/dc09-2241 PMID: 20413516
22. Alkhalaf A, Kleefstra N, Groenier KH, Bilo HJ, Gans RO, et al. (2012) Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy. PLoS One 7: e40427. doi: 10.1371/journal.pone.0040427 PMID: 22792314
23. Beltramo E, Berrone E, Tarallo S, Porta M (2008) Effects of thiamine and benfotiamine on intracellular glucose metabolism and relevance in the prevention of diabetic complications. Acta Diabetol 45: 131-141. doi: 10.1007/s00592-008-0042-y PMID: 18581039
24. Kochi M, Isono N, Niwayama M, Shirakabe K (1985) Antitumor activity of a benzaldehyde derivative. Cancer Treat Rep 69: 533-537. PMID: 4005876
25. Ariyoshi-Kishino K, Hashimoto K, Amano O, Saitoh J, Kochi M, et al. (2010) Tumor-specific cytotoxicity and type of cell death induced by benzaldehyde. Anticancer Res 30: 5069-5076. PMID: 21187492
26. Fraser DA, Hessvik NP, Nikolić N, Aas V, Hanssen KF, et al. (2011) Benfotiamine increases glucose oxidation and downregulates NADPH oxidase 4 expression in cultured human myotubes exposed to both normal and high glucose concentrations. Genes Nutr.
27. Edwards LG, Adesida A, Thornalley PJ (1996) Inhibition of human leukaemia 60 cell growth by S-D-lactoylglutathione in vitro. Mediation by metabolism to N-D-lactoylcysteine and induction of apoptosis. Leuk Res 20: 17-26. PMID: 8632674
28. Hoa NT, Zhang JG, Delgado CL, Myers MP, Callahan LL, et al. (2007) Human monocytes kill M-CSFexpressing glioma cells by BK channel activation. Lab Invest 87: 115-129. PMID: 17318194
29. Bury M, Girault A, Mégalizzi V, Spiegl-Kreinecker S, Mathieu V, et al. (2013) Ophiobolin A induces paraptosis- like cell death in human glioblastoma cells by decreasing BKCa channel activity. Cell Death Dis 4: e561. doi: 10.1038/cddis.2013.85 PMID: 23538442
30. Sperandio S, Poksay K, de Belle I, Lafuente MJ, Liu B, et al. (2004) Paraptosis: mediation by MAP kinases and inhibition by AIP-1/Alix. Cell Death Differ 11: 1066-1075. PMID: 15195070
31. Volvert ML, Seyen S, Piette M, Evrard B, Gangolf M, et al. (2008) Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipidsoluble thiamine disulfide derivatives. BMC Pharmacol 8: 10. doi: 10.1186/1471-2210-8-10 PMID: 18549472
32. Scheibe RJ, Kuehl H, Krautwald S, Meissner JD, Mueller WH (2000) Ecto-alkaline phosphatase activity identified at physiological pH range on intact P19 and HL-60 cells is induced by retinoic acid. J Cell Biochem 76: 420-436. PMID: 10649440
33. Ziems M, Netzel M, Bitsch I (2000) Biokinetic parameters and metabolism of S-benzoylthiamine-O-monophosphate. Biofactors 11: 109-110. PMID: 10705977
34. Marchetti V, Menghini R, Rizza S, Vivanti A, Feccia T, et al. (2006) Benfotiamine counteracts glucose toxicity effects on endothelial progenitor cell differentiation via Akt/FoxO signaling. Diabetes 55: 2231-2237. PMID: 16873685